T1	condition 14 43	anastrozole induced bone loss
T2	intervention 62 73	ibandronate
T4	total-participants 338 341	131
T5	eligibility 342 387	postmenopausal women with early breast cancer
T6	control 653 660	placebo
T7	total-participants 427 429	13
T8	total-participants 448 450	50
T9	total-participants 466 468	68
T10	intervention-participants 772 774	20
T14	control-participants 1028 1030	16
T18	control-participants 1235 1236	8
T3	outcome 1314 1327	change in BMD
T13	outcome 934 937	BMD
T11	outcome 1388 1401	BMD increased
T12	outcome 1161 1180	improvements in BMD
